Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.

ABSTRACT:

Background

Two thrombopoietin receptor agonists (TPO-RA), romiplostim and eltrombopag, are currently widely adopted as second-line ITP therapy even in the absence of robust evidence on their comparative advantages over rituximab or splenectomy or their preferential use in some specific clinical contexts.

Methods

An online survey was distributed between May 2021 and June 2021 to collect standardized information on TPO-RA use in Italy.

Results

Eighty-eight hematologists from 79 centers completed the survey. Eighty-four percent would use TPO-RA earlier than formally indicated, without a preference for young or elderly in 82% of respondents. No clear preference for either romiplostim or eltrombopag was indicated. Seventy-two percent would use TPO-RA in young patients aimi

SUBMITTER: Napolitano M 

PROVIDER: S-EPMC10000838 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature